IP Library Granted Patent US 8,504,383
Granted Patent B1
US 8,504,383 · App. 12/362,082 · Granted Aug 6, 2013

Methods and systems for generic opportunity scoring

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,504,383
App. No.
12/362,082
Granted
Aug 6, 2013
Kind
B1
Abstract

A computer implemented method and/or computer system determines a Generic Opportunity Score (GOS) and/or a generic drug's performance demonstrating how a generic utilization can be better identified and improved relative to the total overall generic opportunity, which can provide savings information relative to a clinically appropriate generic alternative. In some embodiments, the process and/or system determines the GOS as the proportion of generic prescriptions dispensed relative to the maximum number of prescriptions that have a generic equivalent or a clinically-appropriate generic alternative. In some embodiments, the process determines the GOS as the number of generic claims dispensed over the total number of generic claims plus the brand claims that have a generic equivalent or generic alternative. In some embodiments, the data utilized will be provided through a prescription claims database, which can be segmented into three distinct groups: Generic Code Number (GCN), Brand/Generic Code, and Channel, i.e. retail or mail.

Claims (26)

1. A method comprising:

determining, on a processor, a number of generic prescriptions dispensed from claims data;

determining, on the processor, a number of brand name prescription drugs dispensed with a generic equivalent from the claims data, the generic equivalent of a brand name prescription drug being a drug produced after expiration of a patent on the brand name prescription drug that includes the same active ingredients as the prescription drug but is sold under a different brand name through a different manufacturer than the manufacturer of the band name prescription drug;

determining, on the processor, a number of brand name prescription drugs dispensed with a generic alternative from the claims data, the generic alternative used to treat a same condition as the brand name prescription drug but including different chemicals than those included in the brand name prescription drug;

calculating, on the processor, a ratio of the number of generic prescriptions dispensed to a combination of the number of generic prescriptions dispensed, the number of brand name prescription drugs with a generic equivalent, and the number of brand name prescription drugs dispensed with a generic alternative;

determining, on the processor, a total dollar spent on prescription claims for generic prescriptions dispensed and brand prescriptions dispensed included among the claims data;

applying, on the processor, the calculated ratio to the total dollar spent to generate a generic equivalent portion from the total dollar spent; and

determining a potential amount of savings associated with generic drug usage based on the claims data and generation of the generic equivalent portion.

2. The method of claim 1 , further comprising:

sorting the claims data into groups of generic prescriptions dispensed, brand prescription drugs with generic equivalents, and brand prescription drugs with generic alternative data into three groups of data

wherein sorting of the claims data is performed prior to determination of the number of generic prescriptions dispensed, determination of the number of brand name prescriptions dispensed with a generic equivalent, and determination of the number of brand name prescriptions dispensed with a generic alternative.

3. The method of claim 1 , further comprising:

generating price differential data for each brand name prescription among the claims data that could have been fulfilled by at least one of a generic equivalent or clinically-appropriate generic alternative.

4. The method of claim 1 , further comprising:

generating a message to a recipient of a particular brand name prescription drug regarding a particular generic equivalent to the particular brand name prescription drug.

5. The method of claim 1 , wherein the number of generic prescriptions dispensed from claims data included a number of the generic maintenance prescription drugs dispensed, the number of brand name prescription drugs dispensed with a generic equivalent from the claims data include the number of brand name maintenance prescription drugs dispensed with a generic equivalent, and the number of brand name prescription drugs dispensed with a generic alternative from the claims data include the number of brand name maintenance prescription drugs dispensed with a generic alternative, and

wherein calculating the ratio includes calculating the number of generic maintenance prescription drugs dispensed to a combination of the number of generic maintenance prescription drugs dispenses, the number of brand name maintenance prescription drugs with a generic equivalent, and the number of brand name maintenance prescription drugs dispensed with a generic alternative.

6. The method of claim 1 , wherein the number of generic prescriptions dispensed from claims data included a number of the generic acute prescription drugs dispensed, the number of brand name prescription drugs dispensed with a generic equivalent from the claims data include the number of brand name acute prescription drugs dispensed with a generic equivalent, and the number of brand name prescription drugs dispensed with a generic alternative from the claims data include the number of brand name acute prescription drugs dispensed with a generic alternative, and

wherein calculating the ratio includes calculating the number of generic acute prescription drugs dispensed to a combination of the number of generic acute prescription drugs dispenses, the number of brand name acute prescription drugs with a generic equivalent, and the number of brand name acute prescription drugs dispensed with a generic alternative.

7. A non-transitory machine-readable medium comprising instructions, which when executed by one or more processors, cause the one or more processors to perform the following operations:

determine a number of generic prescriptions dispensed from claims data; determine a number of brand name prescription drugs dispensed with a generic equivalent from the claims data, the generic equivalent of a brand name prescription drug being a drug produced after expiration of a patent on the brand name prescription drug that includes the same active ingredients as the prescription drug but is sold under a different brand name through a different manufacturer than the manufacturer of the band name prescription drug;

determine a number of brand name prescription drugs dispensed with a generic alternative from the claims data, the generic alternative used to treat a same condition as the brand name prescription drug but including different chemicals than those included in the brand name prescription drug;

calculate a ratio of the number of generic prescriptions dispensed to a combination of the number of generic prescriptions dispensed, the number of brand name prescription drugs with a generic equivalent, and the number of brand name prescription drugs dispensed with a generic alternative;

determine a total dollar spent on prescription claims for generic prescriptions dispensed and brand prescriptions dispensed included among the claims data;

apply the calculated ratio to the total dollar spent to generate a generic equivalent portion from the total dollar spent; and

determine a potential amount of savings associated with generic drug usage based on the claims data and generation of the generic equivalent portion.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2018
From: MEDCO HEALTH SOLUTIONS, INC.
To: EXPRESS SCRIPTS STRATEGIC DEVELOPMENT, INC.
Reel/Frame 046020/0604 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2009
From: MALLEY, KENNETH; PATEL, KARNIK; BRADBURY, KEITH J.
To: MEDCO HEALTH SOLUTIONS, INC.
Reel/Frame 022888/0022 →